The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours - Yahoo Finance
The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours
For Immediate Release
Chicago, IL – December 26, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Procter & Gamble Co. PG, PepsiCo, Inc. PEP, Novartis AG NVS, Occidental Petroleum Corp. OXY and DuPont de Nemours, Inc. DD.
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Procter & Gamble, PepsiCo and Novartis
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co., PepsiCo, Inc. and Novartis AG. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Procter & Gamble's shares have outperformed the Zacks Soap & Cleaning Materials industry over the last six months (-2.8% vs. -4.0%). The Zacks analyst believes that robust pricing, a favorable mix, strong segments, focus on productivity and cost-saving plans have boosted the company's margins.
However, supply-chain issues, higher SG&A costs and higher transportation costs have been major headwinds. High inflation and foreign currency risks have also been a concern.
(You can read the full research report on Procter & Gamble here >>>)
PepsiCo's shares have underperformed the Zacks Beverages – Soft drinks industry over the past year (-8.4% vs. +1.6%). The Zacks analyst believes that cost pressures driven by impacts of supply-chain disruptions and inflationary labor, transportation and commodity costs have weighed down on the company's performance. Adverse currency rates have also remained a headwind.
Yet, a diversified portfolio, modernized supply chain, improved digital capabilities, flexible go-to-market distribution systems and robust consumer demand trends have gone a long way in turning around third-quarter 2023 for the company, and promises better days ahead.
(You can read the full research report on PepsiCo here >>>)
Shares of Novartis have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+8.0% vs. +4.2%). Per the Zacks analyst, the company's established drug line have continued to fuel growth and offset the impact of generic competition, while new drugs like Pluvicto and Scemblix have witnessed solid launches. The acquisition of Chinook Therapeutics has strengthened its renal pipeline.
However, generic competition for key drugs like Gilenya and pipeline setbacks remain concerns.
(You can read the full research report on Novartis here >>>)
Other noteworthy reports we are featuring today include Occidental Petroleum Corp. and DuPont de Nemours, Inc.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS) : Free Stock Analysis Report
Procter & Gamble Company (The) (PG) : Free Stock Analysis Report
Occidental Petroleum Corporation (OXY) : Free Stock Analysis Report
DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Related Knowledge Center: ENERGY BASICS: nuclear
Nuclear energy provides almost 20 percent of the U.S. electricity supply. Advocates have called for an expanded role for nuclear as an emissions-free fuel source. But the economics of building new reactors are daunting. In addition, lingering safety concerns are an institutionalized part of the calculation of nuclear regulation, and highly radioactive nuclear waste remains a can that public officials have been inclined to kick down the road. The Energy Information Administration projects a sharp decline in nuclear power generation over the next decade, as new nuclear plants — two are planned — are more than offset by anticipated retirements of several operating reactors.